JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i11.12868ArticleAnalysis of the Efficacy of Shexiang Tongxin Dropping Pills Combined with Rosuvastatin Calcium and Clopidogrel Bisulfate Tablets in the Treatment of Phlegm-Heat and Blood Stasis Type Angina Pectoris of Coronary Heart Disease https://artdesignp.com/journal/JCNR/9/11/10.26689/jcnr.v9i11.12868HuChunxia,WangWeifen,WangTianyou,ZhangLing,ZhengDanhua20259112025-12-05Objective: To investigate the clinical efficacy of Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets in treating phlegm-heat and blood stasis type angina pectoris of coronary heart disease. Methods: Sixty-four patients with phlegm-heat and blood stasis type angina pectoris of coronary heart disease, hospitalized at Lin’an District Hospital of Traditional Chinese Medicine from January 2024 to April 2025, were selected and randomly divided into a control group (administered 10mg of rosuvastatin calcium and 75mg of clopidogrel bisulfate once daily) and an observation group (administered 2 Shexiang Tongxin Dropping Pills three times daily in addition to the control group’s treatment regimen), with 32 patients in each group. The therapeutic effects of the two groups were compared. Results: After 56 days of treatment, the angina pectoris score in the observation group was significantly lower than that in the control group (4.49 ± 0.39 vs 4.88 ± 0.47, p < 0.05); the Seattle Angina Questionnaire (SAQ) score indicated improvement in the frequency of angina pectoris attacks. (SAQ-AF: 71.35 ± 5.29 vs. 64.25 ± 7.55, p < 0.05) and treatment satisfaction (SAQ-TS: 58.79 ± 6.22 vs. 54.16 ± 5.02, p < 0.05) were more significantly improved in the observation group. The total effective rate (96.87% vs. 90.62%, p < 0.05) and marked effective rate (62.50% vs. 31.25%) were higher in the observation group than in the control group. The Traditional Chinese Medicine (TCM) syndrome score (4.49 ± 0.39 vs. 4.88 ± 0.47, p < 0.05) and lipid index (LDL-C: 1.79 ± 0.31 vs. 1.99 ± 0.33 mmol/L, p < 0.05) decreased more significantly in the observation group. Conclusion: Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets demonstrated good efficacy and high safety in the treatment of phlegm-heat and blood stasis type angina pectoris associated with coronary heart disease.

Liu M, He X, Yang X, et al., 2024, Interpretation of Report on Cardiovascular Health and Diseases in China 2023. Chinese Journal of Interventional Cardiology, 32(10): 541–550.

Huang X, Li X, Ji H, et al., 2024, A Retrospective Study on the Modern Traditional Chinese Medicine Syndrome Characteristics of Coronary Heart Disease Based on the Clinical Diagnosis and Treatment Data in Tianjin from 2015 to 2021. Journal of Traditional Chinese Medicine, 65(13): 1363–1368.

Huang X, Li X, Yang F, 2023, Literature Research on the Evolution of Syndrome Characteristics of Coronary Heart Disease in Traditional Chinese Medicine From 1970 to 2021. Journal of Traditional Chinese Medicine, 64(10): 1058–1063.

Anonymous, 2016, Anhui Provincial Guidelines for Hierarchical Diagnosis and Treatment of Coronary Heart Disease. Anhui Medical Journal, 37(05): 491–508.

Shang J, Liu H, Li X, 2023, Discussion on the Progress of Diagnosis and Treatment of Coronary Heart Disease Prevention and Treatment with Traditional Chinese Medicine/Integrated Traditional Chinese and Western Medicine Based on Guidelines/Consensus. Beijing Journal of Traditional Chinese Medicine, 42(09): 939–942.

Chen H, 2022, Evidence Evaluation and Consensus Research on the Treatment of Coronary Heart Disease with Shexiang Tongxin Dropping Pills, thesis, Tianjin University of Traditional Chinese Medicine.

World Federation of Chinese Medicine Societies, 2022, International Guidelines for the Diagnosis of Blood Stasis Syndrome (2021-12-16). World Journal of Traditional Chinese Medicine, 17(1): 31–36.

Wu W, Li R, Wu H, et al., 2007, Theoretical Discussion on the Pathogenesis of Heat Toxicity in Coronary Heart Disease. Proceedings of the 9th National Academic Symposium on Traditional Chinese Medicine for Heart Diseases.

Lu H, Li H, Li Z, et al., 2018, Research on the Concept of Etiology and Pathogenesis of Coronary Heart Disease in Traditional Chinese Medicine Based on Modern Literature. Jilin Journal of Traditional Chinese Medicine, 38(05): 497–499.

Lai R, Sheng X, 2009, Discussion on the Correlation Between the Pathogenesis of Heat Toxicity in Coronary Heart Disease and Inflammatory Factors. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, 7(09): 1100–1101.

He H, Dai Z, Gao J, et al., 2024, The Role of Immune Inflammation in Coronary Heart Disease and Research Progress in Traditional Chinese Medicine. World Science and Technology - Modernization of Traditional Chinese Medicine, 26(02): 523–529.

Cortese F, Gesualdo M, Cortese A, et al., 2016, Rosuvastatin: Beyond the Cholesterol-Lowering Effect. Pharmacological Research, 107: 1–18.

Gillette M, Morneau K, Hoang V, et al., 2016, Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. Current Atherosclerosis Reports, 18(6): 35.

Huang X, Kou G, Fan L, et al., 2024, Clinical Research Progress of Shexiang Tongxin Dropping Pills. Journal of Traditional Chinese Medicine Research, 37(09): 92–96.

Ren J, Zhang H, Sun X, et al., 2025, Research on the Efficacy and Quality Control Components of Shexiang Tongxin Dropping Pills in Improving Coronary Heart Disease Based on Fingerprint and Network Pharmacology Correlation Analysis. Traditional Chinese Drug Research and Clinical Pharmacology, 36(02): 262–272.

Yang Y, Ma W, Zhang C, 2024, The Effect of Shexiang Tongxin Dropping Pills Combined with Rosuvastatin in the Treatment of Coronary Heart Disease with Hypercholesterolemia and Its Impact on Liver Function. Medical Innovation of China, 21(11): 24–28.

Xiao S, 2024, The Impact of Different Statins Combined with Clopidogrel on Patients with Coronary Heart Disease and Hyperlipidemia. Medical Innovation of China, 21(32): 126–130.